Company Description
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED.
Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Stephen Mahoney |
Contact Details
Address: 221 Crescent Street, Suite 103A Waltham, Massachusetts 02453 United States | |
| Phone | 617 272 4600 |
| Website | viridiantherapeutics.com |
Stock Details
| Ticker Symbol | VRDN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1590750 |
| CUSIP Number | 92790C104 |
| ISIN Number | US92790C1045 |
| Employer ID | 47-1187261 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen F. Mahoney J.D., MBA | Chief Executive Officer, President and Director |
| Seth Harmon | Chief Financial Officer |
| Thomas W. Beetham J.D., MBA | Chief Operating Officer |
| Jennifer Tousignant J.D. | Chief Legal Officer |
| Dr. Eric N. Olson Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder and Member of the Scientific Advisory Board |
| Dr. Marvin H. Caruthers Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Vahe Bedian Ph.D. | Co-Founder and Scientific Advisor |
| Melissa Manno | Chief Human Resources Officer |
| Anthony Casciano | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Feb 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Dec 31, 2025 | 144 | Filing |